SEC Form 4 · accession 0002001011-26-000106
LIGAND PHARMACEUTICALS INC · LGND
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Todd C Davis
Officer — Chief Executive Officer · Director
Period of report
Jun 30, 2026
Accepted (ET)
Jul 6, 2026 · 5:10 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0000886163
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 30, 2026 | J | 132 | $160.7095 | A | 199,513 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These shares were acquired under the Ligand Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).